BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17845138)

  • 1. Hide-and-seek: the challenge of viral persistence in HIV-1 infection.
    Geeraert L; Kraus G; Pomerantz RJ
    Annu Rev Med; 2008; 59():487-501. PubMed ID: 17845138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
    Saksena NK; Potter SJ
    AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latency: the hidden HIV-1 challenge.
    Marcello A
    Retrovirology; 2006 Jan; 3():7. PubMed ID: 16412247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication.
    Dhamija N; Rawat P; Mitra D
    Subcell Biochem; 2013; 61():479-505. PubMed ID: 23150264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes.
    Redel L; Le Douce V; Cherrier T; Marban C; Janossy A; Aunis D; Van Lint C; Rohr O; Schwartz C
    J Leukoc Biol; 2010 Apr; 87(4):575-88. PubMed ID: 19801499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostratin as a new therapeutic agent targeting HIV viral reservoirs.
    Hezareh M
    Drug News Perspect; 2005 Oct; 18(8):496-500. PubMed ID: 16391719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ludwik Hirszfeld Memorial Lecture: HIV-1 reservoirs: major molecular obstacles to viral eradication.
    Pomerantz RJ
    Arch Immunol Ther Exp (Warsz); 2004; 52(5):297-306. PubMed ID: 15507870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
    Pomerantz RJ
    Clin Infect Dis; 2002 Jan; 34(1):91-7. PubMed ID: 11731950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stochastic population switch may explain the latent reservoir stability and intermittent viral blips in HIV patients on suppressive therapy.
    Wang S; Rong L
    J Theor Biol; 2014 Nov; 360():137-148. PubMed ID: 25016044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 latency and eradication of long-term viral reservoirs.
    Coiras M; Lopez-Huertas MR; Alcami J
    Discov Med; 2010 Mar; 9(46):185-91. PubMed ID: 20350483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.
    Kulkosky J; Pomerantz RJ
    Clin Infect Dis; 2002 Dec; 35(12):1520-6. PubMed ID: 12471572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV reservoirs, latency, and reactivation: prospects for eradication.
    Dahl V; Josefsson L; Palmer S
    Antiviral Res; 2010 Jan; 85(1):286-94. PubMed ID: 19808057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.
    Demonté D; Quivy V; Colette Y; Van Lint C
    Biochem Pharmacol; 2004 Sep; 68(6):1231-8. PubMed ID: 15313421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
    Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of diterpenes from latex of Euphorbia lactea and Euphorbia laurifolia on human immunodeficiency virus type 1 reactivation.
    Avila L; Perez M; Sanchez-Duffhues G; Hernández-Galán R; Muñoz E; Cabezas F; Quiñones W; Torres F; Echeverri F
    Phytochemistry; 2010 Feb; 71(2-3):243-8. PubMed ID: 19897215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HAART-persistent HIV-1 latent reservoirs: their origin, mechanisms of stability and potential strategies for eradication.
    Kulkosky J; Bray S
    Curr HIV Res; 2006 Apr; 4(2):199-208. PubMed ID: 16611058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of HIV-1 proviral latency.
    Bisgrove D; Lewinski M; Bushman F; Verdin E
    Expert Rev Anti Infect Ther; 2005 Oct; 3(5):805-14. PubMed ID: 16207172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.